Compare TG Therapeutics Inc (TGTX) vs Tesla, Inc. (TSLA) Price & Performance

TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.

The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.

Tesla (TSLA) trades at $382.70, up 1.35% today, with a bullish technical signal from moving averages but mixed oscillators. The stock faces high valuation multiples (P/E 347.22, P/S 12.8) amid declining profitability, with net income margin falling to 3.67% in 2025. Recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV launch, though Q2 2026 earnings missed expectations.

Tesla's outlook balances innovation in autonomy and energy against near-term execution risks and competitive pressures. The consensus price target of $441.36 suggests upside, but investors must weigh high valuation, margin compression, and volatile cash flows. Key catalysts include robotaxi progress and demand recovery, while risks involve execution delays and macroeconomic headwinds.